Arnold Etame

Targeting Malignant Reprogramming of Glioblastoma Stem Cells Through Dual Inhibition of S6K1 and BIRC3

National Institute of Neurological Disorders and Stroke · R01

Contact PI · $1.7M · h. Lee Moffitt Cancer Ctr & Res Inst

Exploiting Epigenetic Vulnerabilities In Glioblastoma Stem Cells Through Reprogramming

National Cancer Institute · R21

Contact PI · $433.3K · h. Lee Moffitt Cancer Ctr & Res Inst

Modulating Glioblastoma Stem Cell Clonal Evolution Towards Therapeutic Responsiveness

National Institute of Neurological Disorders and Stroke · R21

Contact PI · $452.9K · h. Lee Moffitt Cancer Ctr & Res Inst

Study to Assess Xevinapant in Preoperative Subjects With Recurrent High-Grade Glioma (rHGG)

Principal investigator · Withdrawn · Phase 1

H. Lee Moffitt Cancer Center and Research Institute

Trial of Therapies With IT cDC1s Combined w/ IT Trastuzamab for Her+ or IT Nivolumab for Her- BC LMD

Sub-investigator · Recruiting · Phase 2

H. Lee Moffitt Cancer Center and Research Institute